Intuitive Surgical is executing a powerful growth and profitability inflection, with revenue growth accelerating to 18.5% in 2026Q2 and operating margin expanding from 24.8% in 2024Q1 to 33.6% in 2026Q2. The company's razor-and-blades model, driven by recurrin...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 18.5% in 2026Q2, with gross margin consistently above 64% (67.8% in 2026Q2) and operating margin expanding to 33.6% from 24.8% in 2024Q1, reflecting strong operating leverage.
Analysts have a consensus rating of 'Strong Buy' with a median price target of $580.00, indicating a potential upside of 27.8%.
Management raised the 2026 procedure growth outlook to 13.5%-15.5%, supported by increased utilization across platforms.
Approximately 75% of ISRG's revenue comes from recurring sources, providing a stable and high-margin revenue stream.
ISRG trades at a high P/E ratio of around 55-58, with some analysts suggesting it could be overvalued by 30.2%.
Procedure growth is projected to slow to 13.5%-15.5% in 2026, down from 18% in 2025.
Factors like tariffs and pricing pressures in China could negatively impact revenue.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 16, 2026 | $2.80+12.9% vs $2.48 | $2.9B+2.4% vs $2.8B |
Q2 2026 Apr 21, 2026 | $2.80+11.6% vs $2.51 | $2.8B+5.8% vs $2.6B |
Q1 2026 Jan 22, 2026 | $2.53+11.5% vs $2.27 | $2.9B+3.7% vs $2.8B |
Q4 2025 Oct 21, 2025 | $2.40+20.6% vs $1.99 | $2.5B+4.1% vs $2.4B |
Abbott Laboratories (ABT +0.54%) primarily generates its revenue by researching, developing, manufacturing, and distributing a diverse portfolio of medical devices, diagnostic test systems, nutritional formulas, and generic pharmaceutical products across international healthcare networks.
Intuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Benchmark ISRG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Intuitive Surgical, Inc. (ISRG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $402.09 | $142.05B | 51.09 | 20.51% | 28.38% | 16.57% | — | |
| $275.07 | $105.45B | 32.75 | 11.16% | 14.43% | 16.36% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $93.98 | $18.18B | 26.47 | 7.2% | 9.48% | 6.36% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
Intuitive Surgical, Inc. (ISRG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Intuitive Surgical, Inc. (ISRG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 16, 2026·SEC
May 28, 2026·SEC
May 4, 2026·SEC
Get notified when ISRG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Intuitive Surgical, Inc. (ISRG) stock FAQ — growth, dividends, profitability & financials explained
Intuitive Surgical, Inc. (ISRG) reported $11.03B in revenue for fiscal year 2025. This represents a 108165% increase from $10.2M in 1999.
Intuitive Surgical, Inc. (ISRG) grew revenue by 20.5% over the past year. This is strong growth.
Yes, Intuitive Surgical, Inc. (ISRG) is profitable, generating $3.14B in net income for fiscal year 2025 (28.4% net margin).
Intuitive Surgical, Inc. (ISRG) has a return on equity (ROE) of 16.6%. This is reasonable for most industries.
Intuitive Surgical, Inc. (ISRG) generated $3.22B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
